Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet

Volumn 385, Issue 9984, 2015, Pages 2288-2295

  Ruff, Christian T ^a   Giugliano, Robert P ^a   Braunwald, Eugene ^a   Morrow, David A ^a   Murphy, Sabina A ^a   Kuder, Julia F ^a   Deenadayalu, Naveen ^a   Jarolim, Petr ^a   Betcher, Joshua ^b   Shi, Minggao ^c   Brown, Karen ^c   Patel, Indravadan ^c   Mercuri, Michele ^c   Antman, Elliott M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b IQVIA   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL FEATURE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERMANENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY ANALYSIS; STUDY DESIGN; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PYRIDINES; STROKE; THIAZOLES; TREATMENT OUTCOME;

EID: 84934289246     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61943-7     Document Type: Article

References (20)

1. AJ Camm, P Kirchhof, GY Lip the European Heart Rhythm Association the European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
2. V Fuster, LE Rydén, DS Cannom the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
3. EM Hylek, AS Go, Y Chang et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
4. RG Hart, LA Pearce, MI Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
5. J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther, G Palareti the American College of Chest Physicians Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 6 suppl 2008 160S 198S
6. E Birman-Deych, MJ Radford, DS Nilasena, BF Gage Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation Stroke 37 2006 1070 1074
7. EM Hylek, C Evans-Molina, C Shea, LE Henault, S Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696
8. SJ Connolly, MD Ezekowitz, S Yusuf the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
9. MR Patel, KW Mahaffey, J Garg the ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
10. CB Granger, JH Alexander, JJ McMurray the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. RP Giugliano, CT Ruff, E Braunwald the ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
12. CT Ruff, RP Giugliano, E Braunwald et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
13. PA Reilly, T Lehr, S Haertter the RE-LY Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-Term anticoagulation therapy) J Am Coll Cardiol 63 2014 321 328
14. CT Ruff, RP Giugliano, EM Antman et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
15. DE Salazar, J Mendell, H Kastrissios et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation Thromb Haemost 107 2012 925 936
16. S Schulman, C Kearon the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
17. JP Piccini, SR Stevens, Y Chang the ROCKET AF Steering Committee and Investigators Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts Circulation 127 2013 224 232
18. BN Beasley, EF Unger, R Temple Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran N Engl J Med 364 2011 1788 1790
19. DM Witt, T Delate, DA Garcia et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding Arch Intern Med 172 2012 1484 1491
20. A Liew, JW Eikelboom, M O'Donnell, RG Hart Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants Can J Cardiol 29 suppl 2013 S34 S44